Vendal retard is utilized for the management of persistent, moderate to severe pain that requires treatment with an opioid analgesic. The medication is typically considered when non-opioid pain relief measures have not sufficiently addressed symptoms. Its primary therapeutic goal is to assist in providing sustained pain relief, thereby supporting patient comfort and aiding in the resumption of functional activities. This may include managing pain associated with conditions like chronic musculoskeletal issues, certain neuropathic discomforts, or prolonged pain following surgical procedures.

“The extended-release formulation aims to contribute to more stable symptom control over an extended duration.”

The approved uses for this medication include the management of pain that necessitates continuous, round-the-clock opioid administration for an extended period.

Quick Fact: Relief for Persistent Moderate to Severe Pain

Vendal retard (Morphine Sulfate Prolonged-Release) is strictly governed by regulatory eligibility rules. The medicine is contraindicated in several specific patient populations to prevent serious, documented risks.

Absolute Prohibitions (Contraindications)

Use is prohibited for patients with significant respiratory depression or acute bronchial asthma, and those with known or suspected gastrointestinal obstruction, including paralytic ileus. The medicine is also contraindicated in cases of acute hepatic disease or known hypersensitivity to morphine. Furthermore, it must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of their discontinuation.

Age and Physiological Restrictions

Age-based rules state that use is contraindicated for children below 1 year of age and is not recommended for those below 12 years due to insufficient safety data. Use during pregnancy and lactation is also not recommended by regulatory authorities.

Conditional Use Requirements

Specific conditions require close caution and potential dose adjustment: patients with severe renal or hepatic impairment should be closely monitored and may require a reduced initial dose. Certain high-dose strengths are officially restricted for use only in opioid-tolerant patients.

Interactions with other medicines and products

The interaction profile of Vendal retard (Morphine Sulfate prolonged-release) is primarily structured around pharmacodynamic effects on the central nervous system (CNS) and pharmacokinetic alterations to drug exposure.

Formal Regulatory Restrictions

Classification	Interacting Substance/Class	Official Constraint
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Must not be co-administered, or used within 14 days of stopping MAOI treatment.
Avoided	Mixed Agonist/Antagonist Opioids (e.g., buprenorphine)	Co-administration should be avoided as it may reduce the analgesic effect or precipitate withdrawal.

Documented Pharmacodynamic and Substance Interactions

Co-administration with other CNS depressants (including sedatives, hypnotics, and general anesthetics) carries a documented, severe risk of additive respiratory depression and profound sedation. This constraint also applies to alcohol (ethanol), which enhances the sedative and hypotensive effects.

Pharmacokinetic and Timing Considerations

Certain medicinal products can modify the drug's plasma exposure. For example, Cimetidine is documented to increase the concentration of morphine, while Rifampicin may reduce it. Pharmacodynamic interaction with Serotonergic Drugs (e.g., SSRIs) is documented to carry a risk of serotonin syndrome.

Due to the prolonged-release formulation, a separation of at least two hours is recommended when co-administering Antacids, to protect the controlled absorption mechanism.

Vendal retard's active substance, morphine, functions as an agonist with high affinity for the mu (mu) opioid receptor (MOR), a G-protein-coupled receptor (GPCR) predominantly located in the central nervous system, including the periaqueductal gray, spinal cord, and regions of the limbic system. Activation of the MOR initiates an intracellular cascade via the G i/ G o subunit. This binding inhibits adenylyl cyclase activity, leading to a decrease in the intracellular concentration of cyclic adenosine monophosphate (cAMP).

Downstream consequences include the opening of G-protein-coupled inwardly rectifying potassium channels ( GIRK), resulting in potassium efflux and hyperpolarization of the neuronal membrane. Simultaneously, voltage-gated calcium channels are inhibited, reducing calcium influx. These actions decrease neuronal excitability and inhibit the release of various neurotransmitters, including substance P and other excitatory mediators, from presynaptic terminals.

The system-level physiological consequence involves the modulation of afferent nociceptive signaling within the spinal cord and altered processing of signals in the brain, leading to a modified perception of input.

Administration Guidelines

Vendal retard is a prolonged-release film-coated tablet for oral use only. The instructions for use mandate a specific procedure to ensure the medicine's extended-release mechanism functions as intended, thereby controlling the delivery of the active substance over time.

Administration Scope	Instruction
Route & Preparation	The tablet must be swallowed whole with a sufficient amount of liquid (e.g., a glass of water). The tablet must not be divided, crushed, or dissolved before administration.
Frequency & Timing	The dose is administered at strictly maintained 12-hour intervals, typically twice a day (morning and evening).
In Relation to Meals	The tablets may be taken with or without food.

Dosing Rules

For adults and adolescents over 12 years, the usual initial dose is typically 10–30 mg of morphine hydrochloride. The dose is adjusted by the doctor based on individual requirements.

• Higher Strengths: Tablets of 60 mg, 100 mg, and 200 mg are not intended for initial dosing.
• Elderly and Impaired Function: Patients who are elderly or have impaired renal or hepatic function require a lower initial dose prescribed by a doctor.
• Children: Use is generally not recommended for children under 12 years due to insufficient experience, and the medicine must not be given to children below 1 year.

Procedural Restrictions

If a dose is forgotten, the patient should take the usual dose immediately upon realizing the omission, and the next dose must then be taken 12 hours later. A double dose must never be taken to compensate for a missed dose.

Research evidence / Overview of studies for Vendal retard

This section summarizes the official clinical research that has evaluated the prolonged-release formulation of morphine sulfate, focusing on the types of studies conducted and the patterns observed, without offering clinical guidance or interpretation of individual outcomes.

---

Evidence for use in Chronic Pain from Advanced Cancer

The most extensive research base for this prolonged-release medication was evaluated in studies involving pain associated with advanced cancer, conditions where symptoms may vary in intensity. The evidence primarily comes from short-term Randomized Controlled Trials (RCTs). These studies examined outcomes related to physical discomfort and changes in pain intensity using validated measurement scales. Research explored the prolonged-release formulation in adult patients involved in continuous, strong opioid administration research.

Comparative evidence describes patterns where the controlled-release formulation was evaluated in studies comparing it to immediate-release morphine products. The primary controlled research focused heavily on short-term periods, typically lasting only one or two weeks. This suggests there is limited information for long-term outcomes.

---

Evidence for use in Chronic Non-Cancer Pain

The prolonged-release formulation was studied for conditions marked by functional limitations and pain that persists outside of a cancer diagnosis. Research in this area includes various RCT designs, sometimes focused on very small groups, alongside systematic reviews. Research explored outcomes reflecting daily functioning or activity level and patient-reported outcomes describing perceived discomfort. Research examined a heterogeneous patient population—meaning the studies included adults with diverse pain conditions.

Systematic reviews of this evidence described patterns where findings were mixed or inconsistent across these varied patient groups. Data derived from these settings typically reflect observations over defined time intervals, with controlled trials running for intermediate-term follow-up periods, such as three to four months. Because of the varying symptom burdens and conditions examined, the generalizability of findings to specific, defined subgroups is limited.

---

What Research Gaps and Uncertainty Remain

A primary limitation is that follow-up durations were limited in many controlled trials, particularly those focused on comparison with other formulations. There is limited information for long-term outcomes. The evidence quality varies across studies due to the heterogeneity of the study populations, which makes it challenging to draw consistent conclusions for specific conditions. Findings describe group patterns, not personal outcomes, and the evidence highlights what is known—and what is still uncertain—about the sustained aspects of the medication.

Common questions about Vendal retard (FAQ)

Q: Is Vendal retard an opioid?

A: Yes, Vendal retard contains morphine, which is classified as an opioid analgesic. According to official product information, it works by acting as an agonist on specific opioid receptors in the body.

Q: What is the difference between Vendal and Vendal retard?

A: Vendal retard is the prolonged-release formulation of the medicine. This means the active substance is released slowly over time, allowing for a longer interval between doses, which is typically 12 hours. Vendal (without retard) is generally the immediate-release version, which has a different duration of effect.

Q: Is it normal to feel tired when taking Vendal retard?

A: Feeling sleepy or drowsy, also known as somnolence, is described in regulatory documents as a common side effect of this medicine. Official information indicates that this can potentially affect up to 1 in 10 users.

Q: What are the most commonly reported side effects of Vendal retard?

A: According to official product information, common side effects—those affecting up to 1 in 10 users—include constipation, nausea, vomiting, and dizziness. Patients should be aware of these documented effects.

Q: Are there any long-term effects of taking Vendal retard that people talk about?

A: The official overview of clinical research notes that most controlled trials were short-term or intermediate-term in duration. This indicates that limited information is available regarding the long-term effects or outcomes of extended use.

Q: What are the signs of a serious side effect from Vendal retard?

A: The most serious risk documented in official safety information is respiratory depression (slow or shallow breathing). Other serious reactions may involve circulatory failure or profound sedation. In the event of a suspected serious reaction, official patient information advises contacting emergency medical services.

Q: Can Vendal retard cause dependence or addiction?

A: Yes, official regulatory documents state that taking Vendal retard for a long period may lead to physical dependence or addiction. They also document that patients may develop tolerance, which means a doctor may need to consider increasing the dose over time to maintain the desired effect.

Q: Is Vendal retard safe for older adults to use?

A: Official information indicates that Vendal retard should be used with caution in older adults. For this patient group, as well as those with impaired liver or kidney function, official guidelines describe a lower initial dose prescribed by a doctor.

Q: Can people with liver problems take Vendal retard?

A: Vendal retard should be used with caution in patients with impaired liver (hepatic) or kidney (renal) function. Official dosing rules specify that these patient groups typically require a lower initial dose prescribed by a doctor.

Q: Is there any information about Vendal retard use during pregnancy?

A: Official warnings state that Vendal retard is generally not recommended for use during pregnancy or labor. If the medication is used during pregnancy, there is a documented risk of neonatal opioid withdrawal syndrome in the newborn.

Q: Can I use Vendal retard if I have a history of breathing problems?

A: Official regulatory warnings indicate that Vendal retard is contraindicated (must not be used) for individuals with significant respiratory depression or acute or severe bronchial asthma. Regulatory warnings mention the risk of respiratory effects associated with the drug.

Q: Has there been much research done on Vendal retard in children?

A: Official documents state that the use of Vendal retard is generally not recommended for children under 12 years of age. This is due to insufficient documented clinical experience regarding its use in this younger population.

Q: What do studies say about the effectiveness of Vendal retard for chronic conditions?

A: Clinical research has explored the prolonged-release formulation for chronic pain conditions not related to cancer. The evidence overview describes that findings were mixed and inconsistent across the diverse patient groups examined in these studies.

Q: Is Vendal retard generally well-tolerated according to research reviews?

A: Studies have specifically examined outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. The research available highlights group patterns of response, rather than personal outcomes.

Q: Are there any specific warnings about driving or operating machinery while on Vendal retard?

A: Official labeling states that this medicine may impair a person's reactivity and their ability to drive or operate machinery. Official labeling states that this matter is typically addressed by a healthcare professional.

Q: Does Vendal retard interact with blood pressure medication?

A: Yes, official drug interaction information notes that co-administration of Vendal retard with antihypertensive medicines (blood pressure medication) may enhance the effects of those medicines.

Q: Does Vendal retard show up on standard drug tests?

A: Vendal retard contains the active substance morphine, which is a substance that may produce positive results in official doping or drug control tests.

Q: Why do some people experience nausea when first taking Vendal retard?

A: Nausea is listed in official documents as a common side effect of Vendal retard. This effect can be expected, as it is documented to affect up to 1 in 10 users.

Q: Is Vendal retard a drug that needs to be tapered off?

A: Official safety information notes that if morphine treatment is suddenly discontinued after long-term use, withdrawal symptoms may develop. Regulatory documents indicate that gradual discontinuation under the oversight of a healthcare professional may be appropriate.

Q: Can Vendal retard affect a person's mood or emotional state?

A: Official documentation lists mood changes, such as confusion, as a potential effect of the medication.

Q: Is Vendal retard considered a controlled substance?

A: As an opioid containing morphine, Vendal retard is subject to strict regulatory controls. It is typically classified as a prescription-only medicine due to its therapeutic classification.

Q: How does the slow-release mechanism in Vendal retard work?

A: Vendal retard is formulated as a prolonged-release tablet designed to steadily release the active substance over a long period. This controlled release is the reason the dose is taken at specific 12-hour intervals.

Q: Is it possible to take too much Vendal retard?

A: Yes, taking more than the prescribed amount is possible. The major risk documented for a Vendal retard overdose is respiratory depression (serious breathing problems).

Q: What does the term 'tolerance' mean in the context of Vendal retard use?

A: Tolerance means the body may adjust to the medication over time. If tolerance develops, regulatory documents indicate that a doctor may need to consider increasing the dose to maintain the desired effect.

Q: Does the time of day matter when taking Vendal retard?

A: The official administration guidelines emphasize that the most important factor in the timing of Vendal retard is maintaining strictly defined 12-hour intervals between doses. This ensures the continuous release of the medicine is maintained.

Q: What does 'contraindication' mean for Vendal retard?

A: A contraindication is a specific condition or circumstance where Vendal retard must not be used because the risk of harm outweighs any potential benefit. For example, official documents state it is contraindicated when taking Monoamine Oxidase Inhibitors (MAOIs).

Q: Do studies suggest that Vendal retard is effective for long-term use?

A: The available clinical research is primarily focused on short-term and intermediate-term periods. The evidence overview highlights that there is limited information available regarding the outcomes of long-term use.

Q: What should I do if I think I'm having an allergic reaction to Vendal retard?

A: Hypersensitivity (an allergic reaction) is listed as a potential risk in official documents. In the event of a suspected serious reaction, official patient information advises contacting emergency medical services.

How to Store and Dispose of Vendal Retard

Vendal retard prolonged-release tablets must be stored according to specific regulatory requirements for strong opioid analgesics.

Storage Requirements

The medicine must be stored at controlled room temperature, generally not exceeding 25 C (77 F), and must be protected from both light and moisture. It is mandatory to keep the product out of the sight and reach of children and pets and secured in its original, tightly closed container to prevent potentially fatal accidental ingestion. The tablets must not be broken, crushed, or chewed, as this compromises the prolonged-release system.

Official Disposal

Unused or expired tablets should not be thrown into household trash or flushed down the toilet (unless specifically advised by the FDA for immediate safety reasons). The preferred method is to utilize an authorized drug take-back program or a registered collection point for disposal of the controlled substance.